Nageshwara Arvind Dasari, MD

Peer-Reviewed Articles

1. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Journal of Clinical Oncology(40):TPS3643-TPS3643, 2022.
2. Amr Mohamed, Sylvia L. Asa, Thomas McCormick, Hilmi Al- Shakhshit, Arvind Dasari, Retuerto Mauricio, Iman Salem, Lee M. Ocuin, David Bajor, Richard T.Lee, J. Eva Selfridge, Arash Kardan, Zhenghong Lee, Norbert Avril, Shelby Kopp, Jordan M. Winter, Jeffery M.Hardacre, John B. Ammori and Mahmoud A. Ghannoum9. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular biology(3):1335-1342, 2022. e-Pub 2022.
3. Maliha Nusrat, Muddassir Ali Syed, Riham Katkhuda, edwin R. Parra, Igacio Ivan Wistuba, Paul Kong, Amanda Koehne, Arvind Dasari, Michael J. Overman, David Menter, Scott Kopetz. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. Journal of Clinical Oncology 40(4):154-154, 2022. e-Pub 2022.
4. Oscar Villarreal, Fadl A. Zeineddine, Ray Chacko, Christine Megerdichian Parseghian, Benny Johnson, Jason Willis, Michael Sangmin Lee, Vaan K. Morris, Arvind Dasari, Kanwal Pratap, Singh Raghav, Michael j. Overman, Y. Nancy You, Yinghong Wang, Dipen M. Maru, John Paul Y.C. Shen, Scott Kopetz. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. Journal of Clinical Oncology 40(4):22-22, 2022. e-Pub 2022.
5. Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, Benny Johnson, Kanwal Pratap Singh Raghav, Arvind Dasari, Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, John Paul Y.C. Shen, Maria Pia Morelli, Alda Tam, Wai Chin Foo, Lianchun Xiao, Scott Kopetz. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Journal of Clinical Oncology 40 40(4):12-12, 2022. e-Pub 2022.
6. Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng C. Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Support Care Cancer 29(12):7351-7354, 2021. e-Pub 2021. PMID: 34050401.
7. Fujii Y, Tzeng CW, Chiang YJ, Halperin DM, Dasari A, Kim MP, Katz MHG, Lee JE, Ikoma N. Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. J Surg Res 268:419-431, 2021. e-Pub 2021. PMID: 34416414.
8. Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract 17(10):OP2000701, 2021. e-Pub 2021. PMID: 33534616.
9. Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open 4(10):e2131744, 2021. e-Pub 2021. PMID: 34705010.
10. Shirali AS, Pieterman CRC, Lewis MA, Hyde SM, Makawita S, Dasari A, Thosani N, Ikoma N, McCutcheon IE, Waguespack SG, Perrier ND. It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. CA Cancer J Clin 71(5):369-380, 2021. e-Pub 2021. PMID: 34061974.
11. Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 17(24):3151-3162, 2021. e-Pub 2021. PMID: 33993740.
12. MacFarlane AW, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother 70(7):1893-1906, 2021. e-Pub 2021. PMID: 33398390.
13. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis 108:419-421, 2021. e-Pub 2021. PMID: 34087489.
14. Arhin ND, Shen C, Bailey CE, Matsuoka LK, Hawkins AT, Holowatyj AN, Ciombor KK, Hopkins MB, Geiger TM, Kam AE, Roth MT, Lebeck Lee CM, Lapelusa M, Dasari A, Eng C. Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Med 10(13):4269-4281, 2021. e-Pub 2021. PMID: 34132476.
15. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2020. PMID: 33229221.
16. Hu ZT, Reinack VH, An J, Indraneel Z, Dasari A, Yang J, Yang EH. Ecofriendly Microencapsulated Phase-Change Materials with Hybrid Core Materials for Thermal Energy Storage and Flame Retardancy. Langmuir 37(21):6380-6387, 2021. e-Pub 2021. PMID: 34000193.
17. Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33916960.
18. Malakorn S, Ouchi A, Hu CY, Sandhu L, Dasari A, You YN, Kopetz ES, Ellis LM, Chang GJ. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clin Colorectal Cancer 20(1):e53-e60, 2021. e-Pub 2020. PMID: 33004292.
19. Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. Curr Oncol Rep 23(4):43, 2021. e-Pub 2021. PMID: 33719003.
20. Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 33(3):e12943, 2021. PMID: 33724586.
21. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2020. PMID: 32960478.
22. William Wong, Rolfy A Perez Holguin, Elizabeth J Olecki, Kelly A Stahi, Matthew Dixon, June Peng, Arvind Dasari, Chan Shen. Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors : Minimally Invasive Surgery for SBNETs. National Library of Medicine- National Center for Biotecnology Information 103(2):125-38, 2021. e-Pub 2021. PMID: 35132564.
23. Kawaguchi Y, Newhook TE, Tran Cao HS, Tzeng CD, Chun YS, Aloia TA, Dasari A, Kopetz S, Vauthey JN. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. J Gastrointest Surg 25(1):186-194, 2021. e-Pub 2020. PMID: 33205306.
24. Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 13:17588359211018047, 2021. e-Pub 2021. PMID: 34093744.
25. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021. PMID: 34367949.
26. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2017. PMID: 29180604.
27. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 124(4):807-815, 2018. e-Pub 2017. PMID: 29211313.
28. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2017. PMID: 29069279.
29. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12):1451-1462, 2017. e-Pub 2017. PMID: 28642335.
30. Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
31. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335-1342, 2017. e-Pub 2017. PMID: 28448665.
32. Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart 103(19):1488-1495, 2017. e-Pub 2017. PMID: 28596302.
33. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
34. Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. (*Both authors contributed equally). Ann Oncol 28(7):1582-1589, 2017. PMID: 28444105.
35. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
36. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
37. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery 161(3):753-759, 2017. e-Pub 2016. PMID: 27816207.
38. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(5):e0173345, 2017. e-Pub 2017. PMID: 28267766.
39. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21(1):155-163, 2017. e-Pub 2016. PMID: 27634306.
40. Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, Kim M, Fleming JB, Katz MH, Lee JE. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. J Gastrointest Surg 20(12):1966-1974, 2016. e-Pub 2016. PMID: 27714644.
41. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2015. PMID: 26810202.
42. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
43. Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist 21(5):563-70, 2016. e-Pub 2016. PMID: 27000464.
44. Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 3(2):175-189, 2016. e-Pub 2016. PMID: 27347369.
45. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist 21(3):308-13, 2016. e-Pub 2016. PMID: 26911407.
46. Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 12(3):313-21, 2016. e-Pub 2016. PMID: 26759064.
47. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and actreotide in advanced well differentiated neuroendocrine tumors. Endocr Relat Cancer 22(15):0002, 2015. e-Pub 2015. PMID: 25900182.
48. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
49. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A phase I dosing finding study in patients with advanced solid malignancies of the oral y-secretase inhibitor PF-03084014. Clin Cancer Res 21(1):60-7, 2015. e-Pub 2014. PMID: 25231399.
50. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
51. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32(4):739-45, 2014. e-Pub 2014. PMID: 24668033.
52. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. (*Both authors contributed equally). Invest New Drugs 31(2):345-54, 2013. e-Pub 2012. PMID: 22615057.
53. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 31(1):115-25, 2013. e-Pub 2012. PMID: 22415798.
54. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med 1(2):207-17, 2012. e-Pub 2012. PMID: 23342270.
55. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. J Clin Oncol 30(19):2348-53, 2012. e-Pub 2012. PMID: 22529266.
56. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH+ tumor-initiating cells that exhibit a gain in notch1 gene copy number have enhanced sensitivity to a γ-secretase inhibitor + irinotecan in colorectal cancer (CRC). Mol Oncol 6(3):370-81, 2012. e-Pub 2012. PMID: 22521243.
57. Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3'UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 18(9):2704-14, 2012. PMID: 22553375.
58. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66(22):10805-14, 2006. PMID: 17108117.
59. Rudek MA, Dasari A, Laheru D, Zhao M, He P, Walker R, Jimeno W, Purcell T, Donehower RC, Hidalgo M, Messersmith WA. Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer (*Both authors contributed equally). Cancer Chemotherapy and Pharmacology 56(8):966-73. e-Pub 2016. PMID: 26632033.
60. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. e-Pub 2021. PMID: 33434908.
61. Chan Shen, PhD1,2; Daniel Tannenbaum, MD3; Robert Horn, MD3; Jane Rogers, PharmD4; Cathy Eng, MD5; Shouhao Zhou, PhD6; Benny Johnson, DO7; Scott Kopetz, MD, PhD7; Van Morris, MD7; Michael Overman, MD7; Christine Parseghian, MD7; George J. Chang, MD, MS8,9; Maria A. Lopez-Olivo, MD, PhD9; Raghav Kanwal, MD7; Lee M. Ellis, MD8; Arvind Dasari, MD, MS7. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. Jama Network(5). e-Pub 2022.
62. Alisha Bent Shreya Raghavan Arvind Dasari Scott Kopetz. The future of ctDNA-defined minimal residual disease: Personalizing adjuvant therapy in CRC. Clinical Colorectal Cancer and Other Gastrointestinal Malignancies. e-Pub 2022.
63. Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tornislav Dragovivh, Seyed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y Nancy You, Robert Anthony Zaiden, Scott Kopetz. Minimal residual disease assessment in colorectal cancer (MiRDA-C). Journal of Clinical Oncology 40(4). e-Pub 2022.
64. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). Journal of Clinical Oncology 40(4). e-Pub 2022.
65. Heloisa P. Soares, Katherine A Guthrie, Syed A. Ahmad, Mary Kay Washington, Brian Hemendra Ramnaraign, Nitya Prabhakar Raj, Carole Seigel, Shay Bellasea, E. Gabriela Chiorean, Arvind Dasari, Jonathan R. Strosberg, Cathy Eng, Philip Agop Philip. Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. Journal of Clinical Oncology 40 40. e-Pub 2022.
66. Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol. e-Pub 2021. PMID: 34787737.
67. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. e-Pub 2021. PMID: 34794903.
68. Strosberg JR, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, Dasari A, Philip P, Soulen MC. Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?. J Nucl Med. e-Pub 2021. PMID: 34556527.
69. Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother:1-10. e-Pub 2021. PMID: 34534031.

Invited Articles

1. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. PMID: 27295529.
2. Dasari A, Yao J. Initial treatment of well differentiated neuroendocrine tumors. Oncology 28(11):945-7, 2014.
3. Dasari A and Messersmith WA. Are additional clinical trials of adjuvant Bevacizumab therapy indicated in colon cancer?. Current Colorectal Cancer Reports 7(3), 2011.
4. Arcaroli JJ, Dasari A, Messersmith WA, Jimeno A. Gamma secretase inhibitors in solid tumor malignancies. Drugs of the Future 36(9):677, 2011.
5. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park) 24(14):1329-34, 2010. PMID: 21294478.
6. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 16(15):3811-8, 2010. e-Pub 2010. PMID: 20554751.

Other Articles

1. Jason A. Willis1,2 and Michael J. Overman1 Inducing Hypermutability to Promote Anti–PD-1 Therapy Response. Cancer Discovery 12(7):1612-1614, 2022.
2. Daniel M. Halperin, MD; Suyu Liu, PhD; Arvind Dasari, MD; David Fogelman, MD; Priya Bhosale, MD; Armeen Mahvash, MD; Jeannelyn S. Estrella, MD; Laura Rubin, PhD; Ajaykumar C. Morani, MBBS, MD; Mark Knafl, MS; Tim A. Overeem, BS; Szu-Chin Fu, PhD; Luisa M. Solis, MD; Edwin Parra Cuentas, MD, PhD; Anuj Verma, MD; Hong-Lei Chen, MD; Swati Gite, MD; Priya Subashchandrabose, MD; Shannon Dervin, PharmD; Katja Schulze, PhD; Walter C. Darbonne, MS; Cindy Yun, PharmD; Ignacio I. Wistuba, MD; P. Andrew Futreal, PhD; Scott E. Woodman, MD, PhD; James C. Yao, MD Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors A Nonrandomized Clinical Trial. JAMA Oncology 3(10):1335-1342, 2022.
3. Arvind Dasari, Chan Shen, Anjali Devabhaktuni, Ruda Nighot, Halfdan Sorbye Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. The Oncologist 27(4):299-306, 2022.
4. Rogers JE, Ohinata A, Dasari A, Eng C Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer 13(1):e1-4, 2014. PMID: 24342822.
5. Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 19(1):e36-41, 2012. PMID: 22328846.
6. Peacock, Oliver BMBS, PhD*; Manisundaram, Naveen MD*; Dibrito, Sandra R. MD, PhD*; Kim, Youngwan MD, PhD*; Hu, Chung-Yuan MPH, PhD*; Bednarski, Brian K. MD*; Konishi, Tsuyoshi MD, PhD*; Stanietzky, Nir MD†; Vikram, Raghu MD†; Kaur, Harmeet MD†; Taggart, Melissa W. MD‡; Dasari, Arvind MD§; Holliday, Emma B. MD∥; You, Y Nancy MD, MHSc*; Chang, George J. MD, MS* Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer after Total Neoadjuvant Therapy (TNT). Annals Of Surgery 10.
7. Newhook, Timothy E. MD∗; Overman, Michael J. MD†; Chun, Yun Shin MD∗; Dasari, Arvind MBBS, MD†; Tzeng, Ching-Wei D. MD∗; Cao, Hop S. Tran MD∗; Raymond, Victoria MS‡; Parseghian, Christine MD†; Johnson, Benny DO†; Nishioka, Yujiro MD, PhD∗; Kawaguchi, Yoshikuni MD, PhD∗; Uppal, Abhineet MD§; Vreeland, Timothy J. MD¶; Jaimovich, Ariel PhD‡; Arvide, Elsa M. PA-C∗; Cristo, Jenilette V. PA-C∗; Wei, Steven H. BA, MPH, MS∗; Raghav, Kanwal P. MD†; Morris, Van K. MD†; Lee, Jeffrey E. MD∗; Kopetz, Scott MD, PhD†; Vauthey, Jean-Nicolas MD∗ Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Annuals of Surgery 10.
8. Alisha Bent Shreya Raghavan Arvind Dasari Scott Kopetz, MD, PhD The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clinical Colorectal Cancer.
9. Arvind Dasari, Chan Shen, Anjali Devabhaktuni, Ruda Nighot, Halfdan Sorbye Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High- Grade Neuroendocrine Carcinomas. The Oncologist.

Editorials

1. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. Journal of Clinical Oncology 35(3):265-267, 2017. PMID: 27893328.
2. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park) 28(9):762-3, 2014. PMID: 25224473.

Abstracts

1. Chun YS, Mehran RJ, Tzeng CD, Kee BK, Dasari NA, Sepsesi B, Conrad C, Aloia TA, Kopetz S, Vauthey JN,. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver meastases from colorectal adenocarcinoma. J Clin Oncol, 2017.
2. Shen C, Chu Y, Dasari A, Zhou S, Halperin DM, Xu Y, Shih YT, Yao JC. Pre-existing symptoms, resource utilization, and healthcare costs prior to diagnosis of neuroendocrine tumors: A SEER-Medicare database study. J Clin Oncol, 2017.
3. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Stein MN, Sanoff HK, Lee JJ, Hansen AR, Malhotra U, Rippke S, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). J Clin Oncol, 2017.
4. Dasari A, Shen C, Chu Y, Halperin DM, Xu Y, Zhou S, Shih T, Yao JC. Prevalence of co-morbidities in elderly patients with distant stage neuroendocrine tumors. J Clin Oncol, 2017.
5. Dasari A, Mehta K, Byers L, Sorbye H, Yao J. Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases. NANETS 2016, 2016.
6. Dasari A, Shen C, Halperin D, Zhou S, Xu Y, Chu Y, Shih T, Yao J. Survival Trends in Neuroendocrine Tumors and Associated Prognostic Factors. NANETS 2016, 2016.
7. Raj N, Chan J, Dasari A, Capanu M, Tang L, Reidy-Lagunes D. A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin. NANETS 2016, 2016.
8. Mehrvarz S, Advani S, Patel M, Dasari A. Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendix. ESMO 2016, 2016.
9. Dasari A, Daniel M. Halperin, Shouhao Zhou, Yiyi Chu, Ying Xu, Tina Shih, James C. Yao, Chan Shen. Clinicopathological and demographic factors associated with development of distant metastasis among patients with locoregional neuroendocrine tumor (NET). J Clin Oncol 34, 2016.
10. Dasari A, Michael J. Overman, David R. Fogelman, Bryan K. Kee, David Menter, Kanwal Pratap Singh Raghav, Van Karlyle Morris, Jisu Oh, Ji Wu, Zhiqin Jiang, Feng Tian, Liana Adam, Mary Brimer, Jeffrey Morris, Funda Meric-Bernstam, Scott Kopetz. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC) 34, 2016.
11. Chan Shen,Dasari A, Shouhao Zhou, Yiyi Chu, Ying Xu, Ya-Chen T. Shih, James C. Yao, Daniel M. Halperin. Functional status of neuroendocrine tumors among elderly patients: A large population-based study using SEER-Medicare data. 2016 ASCO Annual Meeting 34, 2016.
12. Alexandria T. Phan,Dasari A, Nilani Liyanage, David Cox, Susan Pitman Lowenthal, Edward M. Wolin. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 2016 Gastrointestinal Cancer Symposium 34, 2016.
13. Amir Mehrvarz Sarshekeh, Michael J. Overman, Bryan K. Kee, David R. Fogelman,Dasari A, Kanwal Pratap Singh Raghav, Eduardo Vilar Sanchez, Shanequa Manuel, Imad Shureiqui, Robert A. Wolff, Keyur Patel, Rajyalakshmi Luthra, Kenna Rael Shaw, Cathy Eng, Dipen M. Maru, Mark Routbort, Funda Meric-Bernstam, Scott Kopetz. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. 2016 Gastrointestinal Cancer Symposium 34, 2016.
14. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S,Dasari A,. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). 2016 ASCO Annual Meeting 34, 2016.
15. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT,Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33, 2015.
16. Dasari A. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. 2015 ASCO Annual Meeting, 2015.
17. Dasari A, Phan A, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F Yao JC.. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well differentiated neuroendocrine tumors (WD NET). 2014 ASCO Annual Meeting 32(3):232, 2014.
18. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high grade neuroendocrine carcinoma: a single institution experience. ASCO Annual Meeting 32(2):540, 2014.
19. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton, Manuel L, Garrett CR, Sanchez V, Pini E, Shureiqi TM, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarkers screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. GI ASCO Meeting 32(3):540, 2014.
20. Bugano Diniz Gomes D, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off study regorafenib in patients with advanced colorectal cancer. ASCO Annual Meeting 32(3):635, 2014.
21. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton K, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. 2014 Gastrointestinal Cancers Symposium 32, 2014.
22. Hesham M. Hassabo, Ibrahim Halil Sahin, Syed Mohammad Ali Kazmi, Salwan S. Al Mutar, Diogo Bugano Diniz Gomes, Tunghi May Pini, Eduardo Vilar Sanchez,Dasari A,Scott Kopetz, Michael J. Overman, Cathy Eng, Bryan K Kee, Jean-Nicolas Vauthey, Manal Hassan, Chris R. Garrett. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). 2014 Gastrointestinal cancer Symposium 32, 2014.
23. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR,Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting 32:5s, 2014.
24. Dasari A, Gao H, Deaton L, Overman MJ, Hauch S, Kopetz S, Reuben JM. Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. ASCO 2013 Annual Meetings, J Clin Oncol 31, 2013.
25. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. ASCO 2013 Meetings, J Clin Oncol 31, 2013.
26. Powell RW, Tan AC, Varella-Gacia M, Touban B,Dasari A, Puls L, Pitts L, Kulikowski G, Quackenbush K, Messersmith W, Arcaroli JJ. Biomarkers for sensitivity to gamma secretase inhibitors in mouse models of pancreatic adenocarcinoma, 2011.
27. Dasari A, MA Rudek, J Arcaroli.,RW Powell, MA Carducci, D Laheru, JJ Wright, M Hidalgo, WA Messersmith. Tolerance of full-dose sorafenib (S) combined with irinotecan (i;weekly, two on one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). 2011 ASCO Meeting 29(4):522, 2011.
28. Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, Courtney RD, Randoulph S, Shapiro G. A Phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) w ith advanced solid tumors. ASCO 2011 Annual Meeting 29(15):3100, 2011.
29. Dasari A, Gore L, Messersmith AW, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A Phase I Safety and Tolerability Study of Vorinostat (V) in Combination with Sorafenib (S) in Patients With Advanced Solid tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase II Dose (Renal and Non-Small Cell Lung Carcinoma). ASCO Annual Meeting 2010, 2010.
30. Powell RW, Messersmith W, Garcia M, Tan AC, Touban B, Pitts T, Dasari A. The combination of PF03084014 (a γ-secretase inhibitor) and Irinotecan reduces ALDH+ tumor-initiating cells and recurrence in tumors with elevated notch pathway. AACR 2010, 2010.
31. Dasari A,S Malhohrta., CL Spanoletti. A rare complication of a common disease: Pyogenic liver abscess due to diverticulitis. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
32. Malthtra S, A Lertratanakul., Dasari A, CL Spagnoletti. An unusual cause for low back pain: Mycotic abdominal aneurysm. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
33. Dasari A, S Malhotra., CL spagnoletti. Sore Throat - Not always the usual suspect. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.

Book Chapters

1. Dasari A, Yao JC. Pancreatic neuroendocrine tumors. In: Textbook of Complex General Surgical Oncology. McGraw-Hill, 2014.
2. Dasari A, Das P. Could upfront chemotherapy substitute preoperative radiochemotherapy?. In: Multidisciplinary Management of Rectal Cancer - Questions and Answers, 2014.
3. Dasari A, Messersmith WA. Colorectal Cancer. In: Clinical Decision Support System on Oncology, 2008.